ProShare Advisors
NKTR icon

ProShare Advisors’s Nektar Therapeutics NKTR Stock Holding History

ProShare Advisors’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,576
Closed -$26.3K – 2147
2025
Q1 		$26.3K Sell
2,576
-776
-23% -$10.1K ﹤0.01% 2014
2024
Q4 		$46.8K Buy
3,352
+1,103
+49% +$19.5K ﹤0.01% 2185
2024
Q3 		$43.9K Buy
+2,249
New +$42.9K ﹤0.01% 1991
2023
Q4 		– Sell
-829
Closed -$7.4K – 1964
2023
Q3 		$7.4K Buy
829
+13
+2% +$125 ﹤0.01% 1812
2023
Q2 		$7.04K Sell
816
-1,824
-69% -$19.4K ﹤0.01% 1848
2023
Q1 		$27.8K Sell
2,640
-318
-11% -$9.62K ﹤0.01% 1716
2022
Q4 		$100K Buy
2,958
+233
+9% +$11.3K ﹤0.01% 1649
2022
Q3 		$130K Sell
2,725
-161
-6% -$9.58K ﹤0.01% 1500
2022
Q2 		$165K Buy
2,886
+903
+46% +$57K ﹤0.01% 1517
2022
Q1 		$161K Sell
1,983
-444
-18% -$65.7K ﹤0.01% 1938
2021
Q4 		$492K Sell
2,427
-1,327
-35% -$288K ﹤0.01% 1457
2021
Q3 		$1.01M Buy
3,754
+213
+6% +$51.2K ﹤0.01% 905
2021
Q2 		$911K Buy
3,541
+698
+25% +$193K ﹤0.01% 1092
2021
Q1 		$853K Sell
2,843
-154
-5% -$47.9K ﹤0.01% 1089
2020
Q4 		$764K Buy
2,997
+64
+2% +$16.5K ﹤0.01% 1010
2020
Q3 		$730K Buy
2,933
+61
+2% +$19.2K ﹤0.01% 806
2020
Q2 		$998K Buy
2,872
+611
+27% +$191K 0.01% 708
2020
Q1 		$605K Sell
2,261
-1,549
-41% -$479K ﹤0.01% 694
2019
Q4 		$1.23M Sell
3,810
-983
-21% -$285K 0.01% 736
2019
Q3 		$1.31M Sell
4,793
-120
-2% -$44K 0.01% 682
2019
Q2 		$2.62M Sell
4,913
-1,555
-24% -$780K 0.02% 531
2019
Q1 		$3.26M Sell
6,468
-3,433
-35% -$2.03M 0.02% 494
2018
Q4 		$4.88M Buy
9,901
+605
+7% +$365K 0.03% 393
2018
Q3 		$8.5M Buy
9,296
+1,735
+23% +$1.48M 0.06% 271
2018
Q2 		$5.54M Sell
7,561
-329
-4% -$379K 0.04% 418
2018
Q1 		$12.6M Buy
7,890
+165
+2% +$213K 0.08% 193
2017
Q4 		$6.92M Buy
7,725
+724
+10% +$428K 0.05% 364
2017
Q3 		$2.52M Buy
7,001
+664
+10% +$208K 0.02% 515
2017
Q2 		$1.86M Sell
6,337
-432
-6% -$125K 0.02% 582
2017
Q1 		$2.38M Sell
6,769
-1,713
-20% -$385K 0.02% 512
2016
Q4 		$1.56M Buy
8,482
+1,584
+23% +$322K 0.02% 624
2016
Q3 		$1.78M Sell
6,898
-1,123
-14% -$289K 0.02% 521
2016
Q2 		$1.71M Buy
8,021
+155
+2% +$34.6K 0.02% 566
2016
Q1 		$1.62M Sell
7,866
-786
-9% -$151K 0.02% 526
2015
Q4 		$2.19M Buy
8,652
+920
+12% +$189K 0.03% 478
2015
Q3 		$1.27M Sell
7,732
-540
-7% -$95.5K 0.02% 604
2015
Q2 		$1.55M Sell
8,272
-420
-5% -$72.3K 0.02% 596
2015
Q1 		$1.43M Buy
8,692
+1,219
+16% +$251K 0.02% 669
2014
Q4 		$1.74M Sell
7,473
-246
-3% -$52.6K 0.02% 614
2014
Q3 		$1.4M Sell
7,719
-1,850
-19% -$354K 0.02% 926
2014
Q2 		$1.84M Sell
9,569
-5,628
-37% -$995K 0.02% 807
2014
Q1 		$2.76M Buy
15,197
+10,974
+260% +$2.17M 0.03% 562
2013
Q4 		$719K Sell
4,223
-3,562
-46% -$574K 0.01% 1023
2013
Q3 		$1.22M Buy
7,785
+1,173
+18% +$217K 0.03% 726
2013
Q2 		$1.15M Buy
+6,612
New +$1.01M 0.02% 762

Other funds holding NKTR

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

ProShare Advisors's NKTR Position: Q2 2025 in Review

ProShare Advisors sold out of Nektar Therapeutics (NKTR) in Q2 2025, closing a stake of 2,576 shares — an estimated $26.3K sold.

ProShare Advisors first reported a position in NKTR in Q2 2013 and held it in 45 quarters. The position peaked at $12.6M in Q1 2018. 109 funds tracked by Wall St. Rank hold NKTR as of Q2 2025.

  • ProShare Advisors reported no remaining Nektar Therapeutics position as of Q2 2025 after selling out during the quarter.
  • ProShare Advisors sold 2,576 Nektar Therapeutics shares in Q2 2025, an estimated $26.3K.
  • ProShare Advisors first reported a position in Nektar Therapeutics in Q2 2013 and held it in 45 quarters.
  • ProShare Advisors's Nektar Therapeutics position peaked at $12.6M in Q1 2018.
  • 109 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2025.

Based on ProShare Advisors's 13F filing for Q2 2025, filed 7 Aug 2025.